Education
About Us
Working with TipRanks
Follow Us
RSPH - ETF AI Analysis
Top Page
Invesco S&P 500 Equal Weight Health Care ETF (RSPH)
Rating:71Outperform
Price Target:―
Positive Factors
Steady Recent Performance
The ETF has shown positive returns over the past month and three months, indicating solid short-term momentum.
Equal Weighting Strategy
The fund's equal weighting approach reduces reliance on a few large companies, promoting balanced exposure across holdings.
Reasonable Expense Ratio
With a 0.4% expense ratio, the ETF offers relatively low costs compared to actively managed funds.
Negative Factors
Sector Concentration Risk
The ETF is heavily focused on the health care sector, making it vulnerable to industry-specific downturns.
Weak Performance of Key Holdings
Several top holdings, including Moderna and Centene, have underperformed year-to-date, dragging on overall returns.
Limited Geographic Diversification
The ETF is almost entirely invested in U.S. companies, offering little exposure to international markets.
RSPH vs. SPDR S&P 500 ETF (SPY)
AUM759.25M
RegionNorth America
Expense Ratio0.40%
Beta0.58
IssuerInvesco
Inception DateNov 01, 2006
Dividend Yield0.71%
Asset ClassEquity
Index TrackedS&P 500 Equal Weighted / Health Care -SEC
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume54,393
30 Day Avg. Volume68,177
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
36.07Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering61
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RSPH Summary
The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is a fund that focuses on the health care sector, including companies in pharmaceuticals, biotechnology, medical devices, and health care services. Unlike traditional funds, it gives equal weight to each company, ensuring a balanced approach and reducing reliance on larger firms. Some of its holdings include well-known companies like Moderna and Thermo Fisher. Investors might consider this ETF to benefit from the growth and innovation in health care, a sector driven by advancements and aging populations. However, since it focuses solely on health care, its performance is heavily tied to the ups and downs of that industry.
How much will it cost me?The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) has an expense ratio of 0.40%, which means you’ll pay $4 per year for every $1,000 invested. This is slightly higher than average for ETFs because it uses an equal-weight strategy, which requires more active management compared to passively managed funds that track a standard index.
What would affect this ETF?The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) could benefit from advancements in medical technology, increased demand for health care services due to aging populations, and innovation in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, pricing pressures in the health care industry, and potential economic downturns that could reduce consumer spending on health care. Its U.S. focus and equal-weight strategy provide diversification but may limit exposure to faster-growing international markets.
RSPH Top 10 Holdings
The Invesco S&P 500 Equal Weight Health Care ETF is riding the wave of health care innovation, with Eli Lilly leading the charge thanks to its strong pipeline and revenue growth. Cardinal Health is also rising steadily, bolstered by robust cash flow and bullish momentum. However, Intuitive Surgical and Thermo Fisher are showing mixed signals, with high valuations and overbought conditions tempering their outlook. The fund’s focus on U.S.-based health care names ensures exposure to a diverse mix of pharmaceuticals, biotechnology, and medical devices, making it a balanced yet sector-concentrated play on health care advancements.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 2.12% | $16.14M | $971.39B | 36.35% | 72 Outperform | |
| Regeneron | 2.04% | $15.52M | $77.91B | 3.83% | 78 Outperform | |
| Cardinal Health | 2.01% | $15.34M | $47.09B | 71.56% | 66 Neutral | |
| Waters | 1.98% | $15.07M | $22.94B | 3.05% | 70 Outperform | |
| Centene | 1.94% | $14.81M | $20.08B | -31.64% | 58 Neutral | |
| Charles River Labs | 1.94% | $14.81M | $9.50B | 4.25% | 60 Neutral | |
| Intuitive Surgical | 1.87% | $14.25M | $192.25B | 3.23% | 78 Outperform | |
| Biogen | 1.86% | $14.14M | $25.54B | 16.78% | 74 Outperform | |
| Moderna | 1.85% | $14.13M | $11.51B | -28.49% | 58 Neutral | |
| Align Tech | 1.84% | $14.02M | $11.87B | -29.28% | 74 Outperform |
RSPH Technical Analysis
Positive
―
Price Trends
30.93
Positive
29.97
Positive
29.36
Positive
Market Momentum
0.30
Positive
61.18
Neutral
81.95
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RSPH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 31.69, equal to the 50-day MA of 30.93, and equal to the 200-day MA of 29.36, indicating a bullish trend. The MACD of 0.30 indicates Positive momentum. The RSI at 61.18 is Neutral, neither overbought nor oversold. The STOCH value of 81.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RSPH.
RSPH Peer Comparison
Comparison Results
Performance Comparison
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
32.16
2.66
9.02%
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PSCH
Invesco S&P SmallCap Health Care ETF
―
―
―
PTH
Invesco DWA Healthcare Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents